Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06279494
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-21
First Post:
2024-02-09
Brief Title:
SirolimusAbataceptMycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
SirolimusAbataceptMycophenolate Mofetil Regimen for Prophylaxis of Acute Graft-versus-host Disease aGvHD in Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitor
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Graft-versus-host disease GVHD is an important complication after transplantation with an incidence of 40-60 which can increase non-relapse mortality if poorly controlled At present the standard prophylaxis for GVHD is cyclosporine combined with methotrexate However calcineurin inhibitors CNI can cause some vital side effects which are not tolerated by some patients Therefore this study aims to explore the safety and efficacy of Sirolimus in combination with Abatacept and Mycophenolate Mofetil for the prophylaxis of GVHD in patients with haplo-HSCT who are intolerant to calcineurin inhibitors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None